Press Releases

Date	Title and Summary	Additional Formats
Toggle SummaryNov072016	Fate Therapeutics Reports Third Quarter 2016 Financial Results IND Filed for FATE-NK100 Adaptive Natural Killer Cell Immunotherapy in Acute Myeloid Leukemia Orphan Drug Designations for ProTmune Granted by FDA and EMA ProTmune™ PROTECT Clinical Protocol Amended to Facilitate Path for Accelerated Registration SAN DIEGO, Nov. Read All »	View HTML Fate Therapeutics Reports Third Quarter 2016 Financial Results 36.4 KB
Toggle SummaryNov032016	Fate Therapeutics Announces Oral Presentation on Natural Killer Cell Product Candidate FATE-NK100 at the 2016 ASH Annual Meeting Five Additional Presentations to Highlight the Company's Cellular Immunotherapy Programs Read All »	View HTML Fate Therapeutics Announces Oral Presentation on Natural Killer Cell Product Candidate FATE-NK100 at the 2016 ASH Annual Meeting 23.5 KB
Toggle SummaryOct312016	Fate Therapeutics to Webcast Conference Call Reporting Third Quarter 2016 Financial Results on November 7, 2016 SAN DIEGO, Oct. 31, 2016 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that the Company will host a conference call and live audio webcast on Read All »	View HTML Fate Therapeutics to Webcast Conference Call Reporting Third Quarter 2016 Financial Results on November 7, 2016 11.9 KB
Toggle SummaryOct052016	Fate Therapeutics Announces Issuance of U.S. Patent Protecting Enhanced Hematopoietic Stem Cell Compositions Protects Cellular Composition of Lead Immunotherapy Product Candidate ProTmune™ Covers Compositions Generated Using Ex Vivo Modulation to Enhance Stem Cell Properties SAN DIEGO, Oct. 05, 2016 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company dedicated to Read All »	View HTML Fate Therapeutics Announces Issuance of U.S. Patent Protecting Enhanced Hematopoietic Stem Cell Compositions 15.7 KB
Toggle SummarySep262016	Fate Therapeutics Receives FDA Orphan Drug Designation for ProTmune™ in Allogeneic Hematopoietic Cell Transplantation SAN DIEGO, Sept. 26, 2016 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Read All »	View HTML Fate Therapeutics Receives FDA Orphan Drug Designation for ProTmune™ in Allogeneic Hematopoietic Cell Transplantation 16 KB
Toggle SummarySep072016	Fate Therapeutics and Memorial Sloan Kettering Cancer Center Launch Partnership for Development of Off-the-Shelf T-Cell Immunotherapies Unite Cellular Immunotherapy Expertise to Accelerate Clinical Translation of Off-the-Shelf Products Offering Broad Patient Access Collaboration to Use Engineered Pluripotent Cell Lines to Renewably Generate T-Cell Product Candidates Foundational Intellectual Property Covering Pluripotent Read All »	View HTML Fate Therapeutics and Memorial Sloan Kettering Cancer Center Launch Partnership for Development of Off-the-Shelf T-Cell Immunotherapies 19.2 KB
Toggle SummaryAug312016	Fate Therapeutics to Present at Upcoming Investor Conferences SAN DIEGO, Aug. 31, 2016 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announced that Scott Wolchko, President and Chief Executive Officer, will be Read All »	View HTML Fate Therapeutics to Present at Upcoming Investor Conferences 14.2 KB
Toggle SummaryAug102016	Fate Therapeutics to Present at the 2016 Wedbush PacGrow Healthcare Conference SAN DIEGO, Aug. 10, 2016 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that Scott Wolchko, President and Chief Executive Officer, will Read All »	View HTML Fate Therapeutics to Present at the 2016 Wedbush PacGrow Healthcare Conference 11.1 KB
Toggle SummaryAug082016	Fate Therapeutics Reports Second Quarter 2016 Financial Results Opened Patient Enrollment in Phase 1/2 Clinical Trial of ProTmune™ for Prevention of Acute GvHD and CMV Infection IND Filing for Allogeneic Memory-Like NK Cell Cancer Immunotherapy Planned for 2016 Announced $10.3 Million Common Stock Private Placement SAN DIEGO, Aug. Read All »	View HTML Fate Therapeutics Reports Second Quarter 2016 Financial Results 38.3 KB
Toggle SummaryAug082016	Fate Therapeutics Announces $10.3 Million Common Stock Private Placement SAN DIEGO, Aug. 08, 2016 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that it has entered into a securities purchase agreement for a Read All »	View HTML Fate Therapeutics Announces $10.3 Million Common Stock Private Placement 38.3 KB

DISCLOSURE NOTICE: The information contained in each press release is as of the date of the respective press release. The Company assumes no obligation to update any information or forward-looking statement contained in any press release as a result of new information or events or developments arising after the date of such press release.